BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions

The BRAF inhibitors vemurafenib, dabrafenib and encorafenib are used in the treatment of patients with BRAF-mutant melanoma. They selectively target BRAF kinase and thus interfere with the mitogen-activated protein kinase (MAPK) signalling pathway that regulates the proliferation and survival of mel...

Descripción completa

Detalles Bibliográficos
Autores principales: Proietti, Ilaria, Skroza, Nevena, Michelini, Simone, Mambrin, Alessandra, Balduzzi, Veronica, Bernardini, Nicoletta, Marchesiello, Anna, Tolino, Ersilia, Volpe, Salvatore, Maddalena, Patrizia, Di Fraia, Marco, Mangino, Giorgio, Romeo, Giovanna, Potenza, Concetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408709/
https://www.ncbi.nlm.nih.gov/pubmed/32645969
http://dx.doi.org/10.3390/cancers12071823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408709/
https://www.ncbi.nlm.nih.gov/pubmed/32645969
http://dx.doi.org/10.3390/cancers12071823

Ejemplares similares